Enterprise AI Search for Research and Innovation: How RAG and Agentic AI Cut Time to Market Across Industries

The time-to-market problem in research and innovation is rarely a science problem. The science is there — in laboratories, clinical datasets, engineering archives, patent libraries, and the accumulated expertise of thousands of researchers across global organizations. The problem is access. The knowledge that should inform the next decision is distributed across systems that were never designed to work together, in formats that standard search tools cannot process intelligently, often accumulated over decades before anyone thought about how future researchers would find it.

This is the problem that enterprise AI search and Advanced RAG solve for R&D organizations — not by replacing scientific judgment, but by eliminating the information retrieval burden that consumes a measurable and unnecessary portion of research time before that judgment can even be applied.

The five applications below are where the impact concentrates across industries — from pharmaceutical R&D to engineering design to manufacturing innovation. In each case, the mechanism is the same: faster, more complete access to the knowledge that already exists, enabling better decisions made earlier in the research process.

1. Accelerating Knowledge Discovery Across the Full Research Environment

Research organizations have always had a knowledge discovery problem. The relevant information for any research question is distributed across internal systems — ELNs, LIMS, document management platforms, legacy archives — and external sources: scientific literature, patent databases, competitor filings, and regulatory records. Finding it systematically requires knowing which systems to search, how to construct the right queries for each, and how to synthesize results from sources that were never designed to interoperate.

Enterprise AI search addresses this by connecting to the full research data environment — internal and external simultaneously — and enabling researchers to ask questions in natural language rather than constructing system-specific queries. A pharmaceutical researcher asking about the safety profile of a compound class retrieves synthesized intelligence from internal clinical archives alongside the relevant published literature and regulatory filings in a single query. An aerospace engineer asking about prior design decisions for a specific component retrieves the relevant program history from PLM systems alongside the applicable standards documentation.

The productivity impact is direct and measurable. Siemens measured a 30% reduction in engineering research time following Sinequa deployment — a result that reflects engineers spending less time navigating systems and more time applying expertise. At the pharmaceutical level, UCB documented $143M per year in R&D value from improved scientific knowledge access. In both cases, the underlying mechanism is the same: researchers reaching the relevant knowledge faster, and making better-informed decisions as a result.

According to research consistently cited across the industry, approximately 80% of R&D data in life sciences is unstructured — living in documents, images, clinical narratives, and research notes rather than structured databases. Enterprise AI search with semantic retrieval handles this unstructured content as fluently as it handles structured data, making the full knowledge base accessible rather than only the structured fraction that traditional analytics tools can query.

2. Enabling Cross-Disciplinary Collaboration at Enterprise Scale

Innovation in complex industries is rarely the product of a single discipline working in isolation. Drug development requires alignment between medicinal chemists, pharmacologists, clinical scientists, regulatory affairs specialists, and manufacturing development teams. Engineering programs require coordination between design engineers, materials specialists, manufacturing engineers, quality teams, and supply chain. The knowledge each discipline needs exists — but it is frequently invisible across organizational boundaries because each team works in the systems relevant to their function, without access to the knowledge accumulated by adjacent teams working on the same program.

Enterprise AI agents make cross-disciplinary knowledge visible by connecting to all of these functional systems simultaneously and enabling any team member to query the full organizational knowledge base, not just the subset relevant to their own function. A regulatory affairs specialist can access the relevant clinical data context. A manufacturing development engineer can access the formulation rationale documented by the chemistry team. A clinical scientist can surface the relevant preclinical findings from a study completed before they joined the program.

Airbus deployed this capability across more than 700 engineers in aerospace design and manufacturing — giving every engineer on the platform access to the institutional knowledge accumulated across one of the world’s most technically complex manufacturing organizations, regardless of which team or system that knowledge originated in. The collaboration acceleration is not about communication tools — it is about knowledge visibility that makes cross-functional teams genuinely informed about each other’s work.

For pharmaceutical organizations, this cross-disciplinary intelligence layer is particularly valuable during late-stage development, when regulatory, clinical, manufacturing, and commercial teams must align on development strategy simultaneously, and where the cost of a misalignment discovered late is measured in months of approval delay.

3. Predictive Intelligence: Moving from Reactive Research to Proactive Decision-Making

Traditional research processes are largely reactive: a hypothesis is tested, results are generated, and the results inform the next decision. The limitation of this model is that the decision about which hypothesis to test next — which compound to advance, which engineering approach to pursue, which market to enter — is made with partial information, because assembling the full relevant evidence base for a strategic research decision takes more time than research cadences allow.

AI agents with access to the full organizational knowledge base change this by enabling proactive intelligence synthesis. Before a research team commits to a development direction, an AI agent can surface the relevant prior evidence — internal program history, published scientific literature, competitor pipeline intelligence, regulatory precedent — and generate a synthesized intelligence briefing that reflects the current state of knowledge on that direction. The decision is made with the full evidence base assembled, not the subset that was accessible within the time available for manual review.

In pharmaceutical R&D, this proactive intelligence layer is most valuable at compound selection and portfolio prioritization decisions — the moments when development investment is committed and the cost of a wrong decision is highest. The ability to systematically surface the prior evidence for any compound or target decision, rather than relying on the individual knowledge of the scientists present in the room, materially improves the quality of those decisions.

4. Personalizing the Research Experience for Different Knowledge Needs

R&D organizations span a wide range of expertise levels and knowledge needs. A senior scientist with twenty years of experience on a compound class has fundamentally different information needs than a researcher joining the program for the first time. A lead engineer with deep domain knowledge needs different context than a project manager coordinating across functions. A regulatory affairs director needs different synthesis than a biostatistician analyzing clinical data.

Enterprise AI search with Advanced RAG naturally adapts to these different knowledge needs through the specificity of the query rather than requiring manual configuration of different search profiles. A researcher asking a highly specific technical question receives a response calibrated to the technical depth of the question. A program manager asking for a status overview receives a synthesized program summary. The same platform serves the full spectrum of knowledge needs across an R&D organization without requiring separate tools for different user types.

This personalization also applies to access permissions: enterprise AI security enforces role-based access controls at the retrieval layer, ensuring that each user’s AI-powered knowledge access is constrained to the information they are authorized to see. Sensitive pre-submission regulatory strategy, competitive intelligence, and proprietary compound data are protected without requiring researchers to navigate complex manual access request processes — the system simply serves each user the knowledge they are permitted to access, automatically.

5. Simplifying Regulatory Intelligence and Compliance Readiness

Regulatory compliance is a knowledge problem as much as it is a process problem. The challenge of maintaining regulatory readiness — ensuring that the relevant standards, guidance documents, prior submission precedents, and agency correspondence are integrated into development decisions — is fundamentally a challenge of keeping the organization’s working knowledge of the regulatory landscape current and accessible.

Compliance and risk management workflows powered by enterprise AI give regulatory and quality teams real-time access to the full regulatory knowledge base: FDA and EMA guidance documents, advisory committee proceedings, competitor approval packages, prior submission history, and the relevant standards documentation for any jurisdiction and indication. Rather than assembling this information manually for each regulatory decision, teams can query it in natural language and receive synthesized intelligence with citations to the specific regulatory sources that are most relevant.

The operational impact spans the full development lifecycle. During early development, regulatory intelligence synthesis helps shape development strategies around the evidentiary standards most likely to support approval. During submission preparation, AI-powered synthesis of the prior submission history and agency correspondence compresses the preparation timeline. During post-approval surveillance, AI agents monitoring regulatory intelligence sources flag relevant guideline changes, competitor label updates, and agency signals that should inform the organization’s regulatory strategy in real time.

Pfizer, AstraZeneca, GSK, and Novartis have deployed Sinequa’s enterprise agentic AI platform to support regulatory intelligence and compliance workflows alongside scientific research and clinical development operations.

The R&D Acceleration Architecture

Across all five applications, the same architectural foundation determines whether the benefits described above are realizable in practice: comprehensive data connectivity, semantic retrieval quality, and governance.

Comprehensive connectivity means the AI system reaches the full research data environment — not a curated subset of recent, clean, structured data, but the complete institutional knowledge base including legacy archives, specialized research databases, and external scientific content. The organizational knowledge that is most valuable for research decisions is often older and less accessible, not newer and more visible.

Semantic retrieval quality means the system understands the terminology and conceptual relationships of the specific research domain — pharmaceutical, engineering, or otherwise — well enough to retrieve the genuinely relevant content rather than keyword-matched content that happens to contain the search terms. For R&D applications, where the relevant content often uses specialized terminology and domain-specific conceptual relationships, this semantic intelligence is the difference between a system that researchers trust and one they abandon after initial trials.

And governance means that the efficiency gains of AI-powered knowledge access are achieved without compromising the information security, IP protection, and regulatory compliance requirements that research organizations cannot relax regardless of how compelling the efficiency gain.

These three properties together describe what Sinequa’s enterprise AI platform delivers for R&D organizations across industries — and why the results documented above are achievable in production rather than limited to controlled pilot conditions.